NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · AMPE · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ampio Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$6.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ampio Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$6.000.0% vs estimate |
| $0.00 |
| Q1 2022 | May 16, 2022 | -$9.00-50.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$7.44+$0.32 (+4.49%)
Avalo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.34% below the high.
$8.83+$0.03 (+0.34%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
$1.05-$0.04 (-3.24%)
Stablecoin Development Corp.’s quoted price sits in the lower half of its reported 52-week range, 89.33% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$1.22+$0.03 (+2.52%)
Alzamend Neuro Inc’s quoted price sits in the lower half of its reported 52-week range, 54.48% below the high.
$1.32+$0.12 (+10.0%)
Virax Biolabs Group Limited’s quoted price sits in the lower half of its reported 52-week range, 93.93% below the high.
$0.37-$0.01 (-1.53%)
Oragenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.99% below the high.
